William Blair Brokers Lift Earnings Estimates for Danaher

Key Points

• William Blair raised its Q2 2026 earnings estimate for Danaher to $2.02 per share, up from a previous forecast of $1.86.
• Danaher recently reported earnings of $1.80 EPS, exceeding analysts' expectations of $1.64 for the quarter, with revenues of $5.94 billion.
• The company announced a quarterly dividend of $0.32 per share, yielding approximately 0.63%.

Danaher Corporation (NYSE:DHR - Free Report) - Equities researchers at William Blair increased their Q2 2026 earnings estimates for Danaher in a research report issued to clients and investors on Wednesday, July 23rd. William Blair analyst M. Larew now forecasts that the conglomerate will post earnings of $2.02 per share for the quarter, up from their prior forecast of $1.86. The consensus estimate for Danaher's current full-year earnings is $7.63 per share.

Other equities analysts also recently issued research reports about the stock. HSBC dropped their price objective on shares of Danaher from $270.00 to $240.00 in a report on Friday, April 25th. Wells Fargo & Company cut their price objective on Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research note on Wednesday. Deutsche Bank Aktiengesellschaft cut their price objective on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Bank of America lowered their target price on shares of Danaher from $265.00 to $230.00 in a research note on Monday, April 14th. Finally, JPMorgan Chase & Co. lowered their price target on Danaher from $280.00 to $260.00 and set an "overweight" rating on the stock in a report on Tuesday, April 22nd. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat, Danaher presently has a consensus rating of "Moderate Buy" and a consensus price target of $247.61.

Danaher Stock Performance

DHR opened at $203.21 on Friday. The company has a current ratio of 1.62, a quick ratio of 1.05 and a debt-to-equity ratio of 0.32. The company has a market cap of $145.43 billion, a price-to-earnings ratio of 43.24, a PEG ratio of 2.75 and a beta of 0.77. The company's 50 day moving average is $196.19 and its 200 day moving average is $204.15. Danaher has a 12-month low of $171.00 and a 12-month high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm's revenue was up 3.4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.72 earnings per share.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.63%. Danaher's payout ratio is currently 27.23%.

Insider Activity

In other news, Chairman Steven M. Rales sold 1,250,000 shares of the company's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the transaction, the chairman owned 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. This represents a 28.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Christopher Paul Riley sold 15,805 shares of the company's stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the transaction, the executive vice president directly owned 15,179 shares in the company, valued at approximately $3,005,442. This represents a 51.01% decrease in their position. The disclosure for this sale can be found here. 11.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Fortis Capital Advisors LLC grew its stake in Danaher by 1.3% in the 4th quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate's stock worth $914,000 after acquiring an additional 50 shares in the last quarter. Fayez Sarofim & Co grew its stake in Danaher by 0.6% in the 4th quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock worth $1,902,000 after acquiring an additional 50 shares in the last quarter. Coastal Bridge Advisors LLC grew its stake in Danaher by 4.8% in the 4th quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock worth $252,000 after acquiring an additional 50 shares in the last quarter. Perennial Investment Advisors LLC grew its stake in Danaher by 2.2% in the 4th quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate's stock worth $538,000 after acquiring an additional 51 shares in the last quarter. Finally, MGO One Seven LLC grew its stake in Danaher by 1.3% in the 4th quarter. MGO One Seven LLC now owns 4,285 shares of the conglomerate's stock worth $984,000 after acquiring an additional 53 shares in the last quarter. Institutional investors own 79.05% of the company's stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.